Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).

OBJECTIVE: To describe the incidence and outcomes of endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor agents in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and to assess the effect of prophylactic topical antimicrobials on incidence. DESIGN: Cohort study within a randomized clinical trial. PARTICIPANTS: Patients enrolled in CATT. METHODS: Patients with neovascular age-related macular degeneration received intravitreal injections of ranibizumab or bevacizumab under 1 of 3 dosing regimens. The study protocol specified preinjection preparation to include use of a sterile lid speculum and povidone iodine (5%). Use of preinjection and postinjection antibiotics was at the discretion of the treating ophthalmologist. Patients were followed up monthly for 2 years. MAIN OUTCOME MEASURES: Development of endophthalmitis and visual acuity. RESULTS: Endophthalmitis developed after 11 of 18 509 injections (1 per 1700 [0.06%]; 95% confidence interval, 0.03%-0.11%), and in 11 of 1185 patients (0.93%; 95% confidence interval, 0.52-1.66). Incidence of endophthalmitis was 0.15% among injections with no antibiotic use, 0.08% among injections with preinjection antibiotics only, 0.06% among injections with postinjection antibiotics only, and 0.04% among injections with preinjection and postinjection antibiotics (P = 0.20). All eyes were treated with intravitreal antibiotics and 4 underwent vitrectomy. Among the 11 affected eyes, the final study visual acuity was 20/40 or better in 4 eyes (36%), 20/50 to 20/80 in 2 eyes (18%), 20/100 to 20/160 in 3 eyes (27%), and worse than 20/800 in 2 eyes (18%). The final visual acuity was within 2 lines of the visual acuity before endophthalmitis in 5 eyes (45%). CONCLUSIONS: Rates of endophthalmitis were low and similar to those in other large-scale studies. Use of topical antibiotics either before or after injection does not seem to reduce the risk for endophthalmitis.

Hemorrhagic unilateral retinopathy.

PURPOSE: To evaluate the possible etiologies of a hemorrhagic unilateral retinopathy in healthy patients. METHODS: Retrospective case series and review of the literature. All patients underwent a detailed ophthalmologic evaluation and analyses of their medical histories. RESULTS: Eleven eyes of 10 patients with unexplained unilateral, predominantly deep, intraretinal hemorrhages were identified. All patients were women. Mean age of the subjects was 48.4 years (range, 25-83 years). The main complaint at presentation was sudden visual loss, with visual acuity ranging from 20/20 to hand motion. The mean follow-up was 17 months, and the 9 eyes with follow-up showed spontaneous resolution of the hemorrhages and marked improvement of vision. There was no history of Valsalva maneuver or strenuous exercise. The patients were healthy at presentation and during follow-ups as long as 84 months. CONCLUSION: This series depicts the characteristics of a possible new entity with a review of the differential diagnosis. The visual outcome was excellent.

Immediate hyphema after intravitreal injections of ranibizumab.

PURPOSE: To report two cases of immediate hyphema formation after the intravitreal injection of ranibizumab. METHODS: Retrospective case reports. RESULTS: A patient with choroidal neovascularization caused by exudative age-related macular degeneration and a patient with cystoid macular edema caused by branch retinal vein occlusion underwent an intravitreal injection of 0.5 mg/0.05 mL of ranibizumab. The development of hyphema was seen immediately after the intravitreal injection in both cases. One patient was pseudophakic, taking 325 mg of aspirin daily. The other patient was phakic without any anticoagulation history. CONCLUSION: To the best of our knowledge, this is the third report of the development of hyphema associated with intravitreal injections.

Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment.

PURPOSE: To describe the course of cytomegalovirus (CMV) retinitis in patients with AIDS in the era of highly active antiretroviral therapy (HAART). DESIGN: Multicenter, prospective, observational study. PARTICIPANTS: Two hundred seventy-one patients with AIDS and CMV retinitis. METHODS: Follow-up every 3 months with medical history, ophthalmologic examination, laboratory testing, and fundus photographs. MAIN OUTCOME MEASURE: Second (contralateral) eye involvement among patients with unilateral disease and retinal detachment (RD). RESULTS: The overall rate of second eye involvement among patients with unilateral CMV retinitis was 0.07 per person-year (PY); among those with CD4+ T-cell counts of <50/microl it was 0.34/PY, compared with 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). Risk factors for contralateral eye involvement included low CD4+ T-cell count and detectable CMV load. The overall rate of RD was 0.06/PY; among those with CD4+ T-cell counts of <50/microl it was 0.30/PY, compared with 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). Risk factors for RD included a low CD4+ T-cell count and larger area of CMV retinitis. CONCLUSIONS: Compared with the rates reported in the pre-HAART era of second eye involvement (approximately 0.40/PY) and RD (approximately 0.50/PY), the rates of these events were reduced among patients in the HAART era. However, among patients with CD4+ T-cell counts of <50/microl, the rates were more similar to those from the pre-HAART era.

Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression.

PURPOSE: To describe the course of cytomegalovirus (CMV) retinitis in patients with AIDS in the era of highly active antiretroviral therapy (HAART). DESIGN: Multicenter, prospective, observational study. PARTICIPANTS: Two hundred seventy-one patients with AIDS and CMV retinitis. METHODS: Follow-up every 3 months with medical history, ophthalmologic examination, laboratory testing, and fundus photographs. Photographs were evaluated for relapse of the retinitis (progression) by graders at a centralized reading center. MAIN OUTCOME MEASURE: Retinitis progression (movement of the border of a CMV lesion > or =750 microm over a > or =750-microm front or occurrence of a new lesion one-quarter disc area or more in size). RESULTS: The overall rate of retinitis progression was 0.10/person-year (PY); among those with CD4+ T-cell counts of <50/microl, it was 0.58/PY, compared to 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). In the multivariate analysis, significant risk factors for retinitis progression included a low CD4+ T-cell count, positive CMV load, longer time from AIDS diagnosis, and low Karnofsky score. CONCLUSIONS: Compared with the rate of retinitis progression (approximately 3.0/PY) reported in the pre-HAART era, the rate of retinitis progression was reduced among patients in the HAART era, even among those with low CD4+ T-cell counts, who might be expected to behave most like patients from the pre-HAART era. However, these events also occurred among patients with high CD4+ T-cell counts and presumed immune recovery. Continued ophthalmologic follow-up of patients with immune recovery is recommended to detect early retinitis progression.

Thyroid function and pregnancy status in broodmares.

OBJECTIVE: To determine whether thyroid function was associated with pregnancy status in broodmares. DESIGN: Prospective study. ANIMALS: 79 Thoroughbred and Standardbred broodmares between 2 and 22 years old. PROCEDURE: Serum triiodothyronine (T3) concentration was measured before and 2 hours after i.v. administration of thyrotropin releasing hormone (TRH), and serum thyroxine (T4) concentration was measured before and 4 hours after TRH administration. Pregnancy status was monitored by means of transrectal ultrasonography beginning 16 days after ovulation. RESULTS: Baseline T3 and T4 concentrations varied widely. In all mares, serumT3 concentration increased in response to TRH administration. Serum T4 concentration increased in response toTRH administration in all but 2 mares. Pregnancy rate was 76%. Baseline and stimulated serum T3 and T4 concentrations were not significantly different between mares that became pregnant and those that did not. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that decreased thyroid function is uncommon in mares and poor thyroid function is not a common cause of infertility. Thus, the practice of indiscriminately treating broodmares with thyroid hormone to enhance fertility appears questionable at this time.

Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas.

PURPOSE: To examine the outcomes and complications of transpupillary thermotherapy for treatment of small choroidal melanomas. DESIGN: Retrospective case-matched comparative study and retrospective observational study. PARTICIPANTS: The case-matched study consisted of 36 patients treated with either transpupillary thermotherapy or plaque radiotherapy (18 patients per group). The observational study consisted of 21 patients treated with transpupillary thermotherapy alone (primary transpupillary thermotherapy) and 9 patients treated with transpupillary thermotherapy plus plaque radiotherapy (adjuvant transpupillary thermotherapy). MAIN OUTCOME MEASURES: Visual acuity, local tumor control, and metastasis. RESULTS: The case-matched groups did not differ significantly with respect to age, gender, initial visual acuity, tumor location, or length of follow-up (mean, 33 months for transpupillary thermotherapy vs. 40 months for plaque radiotherapy). There was no significant difference in final visual acuity (P = 0.810) or postoperative visual acuity change (P = 0.919) between the 2 groups. In the observational study, the mean follow-up was 32 months (range, 4-58 months). Indications for primary transpupillary thermotherapy included documented growth (10 patients) and the presence of >/=3 risk factors for growth (11 patients). Retinal complications occurred in 16 patients (76%). The mean posttreatment visual acuity change was minus 2 lines (range, minus 9 to plus 7 lines). Local failure occurred in 6 patients (29%). Local failure was associated with an increased number of transpupillary thermotherapy spots per session (P = 0.023) and decreased tumor pigmentation (P = 0.001). Indications for adjuvant transpupillary thermotherapy included tumor radioresistance (6 patients) and the presence of risk factors for local failure (3 patients). All 9 tumors that received adjuvant transpupillary thermotherapy regressed rapidly, with no local failures. The mean postoperative visual acuity change was -1.9 lines (range, -9 to +5 lines). No patient in either study developed metastasis. CONCLUSIONS: The recent interest in transpupillary thermotherapy as primary therapy for choroidal melanoma is based largely on the assumption that transpupillary thermotherapy may provide better visual outcomes than plaque radiotherapy. However, this study found no significant difference in visual outcomes between transpupillary thermotherapy and plaque radiotherapy. Further, the local failure rate with transpupillary thermotherapy was substantially higher than with plaque radiotherapy. The most promising role for transpupillary thermotherapy seems to be as an adjunct to plaque radiotherapy. The appropriate indications for transpupillary thermotherapy in the management of choroidal melanoma need to be re-evaluated.